Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in developing therapies that enable the immune system to attack tumors. Through the use of its Translational Science Platform, the Company first focuses on specific cell types within tumors to prioritize targets, and then identify related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator (ICOS), a protein on the surface of certain T cells found in a range of solid tumors. The Company has initiated JTX-2011 multi-arm Phase I/II clinical trial in patients with solid tumors. The Company is also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. The Company is developing JTX-4014, a fully human Immunoglobulin G 4 (IgG4) monoclonal antibody.